Inside Medical Technology

11 - 12 April 2018 // Nuremberg, Germany

This is what MT-CONNECT and MedTech Summit 2018 have to offer.

back to day overview
Frugal Innovations in Medicine

ITOS Mass Screening – Automatic Eye-Screening for early diagnosis of diabetic retinopathy Vortragssprache Deutsch Simultanübersetzung Englisch

Diabetic retinopathy as a sequela of diabetes can lead to severe visual impairment and blindness. This can be avoided by timely diagnosis and intervention in most cases. The necessary annual ophthalmological control reaches only 50% of diabetics. With ITOS Mass Screening significantly more diabetics can be included in the care.

For diabetics worldwide, the danger of becoming blind due to diabetic retinopathy remains high. In Argentina, every 4 hours one diabetic goes blind, in Brazil every 2 hours, in Mexico every hour. In Germany, approximately 1,200 diabetics go blind each year within the scope of the statutory health insurance. Much of the blindness can be avoided if diabetic retinopathy is detected and treated early. Regular check-ups are necessary for this. In practice, however, only a small proportion of diabetics are regularly examined by ophthalmologists. In Mexico, for example, only affects 20% of all diabetics. Even in Germany, the proportion is only about 50%.

The situation can be improved by using automated procedures. Eye fundus images taken with a fundus camera can be evaluated using modern image processing techniques and analyzed for features indicative of diabetic retinopathy.

With Voigtmann GmbH’s “Integrated Tele-Ophthalmological System ITOS”, mass screenings for the early recognition of diabetic retinopathy can be automated. ITOS is a cost-efficient and effective procedure, which can be carried out without the involvement of medical professionals. In distributed screening stations, the fundus photographs of patients are acquired and analyzed automatically. When indications of diabetic retinopathy are found, the patient is referred to an ophthalmologic center. This allows for decentral identification of the few patients in need of ophthalmological treatment out of a much larger risk group.

Clinical investigations have resulted in the following parameters for ITOS:
Sensitivity (true-positive-rate): 85.5%, (74.2% - 93.1%)
Specificity (true-negative rate): 90.9%, (87.3% - 93.8%)

ITOS is a Class IIa medical device, certified by TÜV Rheinland.

--- Date: 12.04.2018 Time: 10:00 AM - 10:15 AM Location: Hall Brüssel II, NCC Mitte

Speakers

Dipl.-Kfm. Peter Voigtmann

Dipl.-Kfm. Peter Voigtmann

CEO / Voigtmann GmbH

top

The selected entry has been placed in your favourites!

If you register you can save your favourites permanently and access all entries even when underway – via laptop or tablet.

You can register an account here to save your settings in the Exhibitors and Products Database and as well as in the Supporting Programme.The registration is not for the TicketShop and ExhibitorShop.

Register now

Your advantages at a glance:

  • Advantage Save your favourites permanently. Use the instant access to exhibitors or products saved – mobile too, anytime and anywhere – incl. memo function.
  • Advantage The optional newsletter gives you regular up-to-date information about new exhibitors and products – matched to your interests.
  • Advantage Call up your favourites mobile too! Simply log in and access them at anytime.